Clin2
NCT06092346Possibly a fitRecruiting

Understanding rare purine and pyrimidine metabolism disorders

AMPD3, OMIM*102772, AMP Deaminase DeficiencyAK1, OMIM *103000, Adenylate Kinase DeficiencyAMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase DeficiencyTPMT, OMIM *187680, Thoipurines, Poor Metabolism ofIMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11APRT, OMIM *102600, Adenine Phosphoribosyltransferase DeficiencyHPRT1, OMIM *308000 Lesch-Nyhan DiseaseXDH, OMIM *607633, Xanthinuria Type 1

Part of Blood & lymphatic, Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism, Immune system & allergy, Skin clinical trials.

This study aims to learn more about rare disorders of purine and pyrimidine metabolism (DPPM), which can affect the brain, immune system, kidneys, and muscles. Researchers will study people with these disorders, their family members, and healthy volunteers to better understand the condition over time.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
999 people
Ages
1 month to 100 years
Study type
Observational

Who can take part

  • You (or your family member) must be at least one month old.
  • You must either have or be suspected of having a disorder of purine and pyrimidine metabolism (DPPM), or be a family member of someone who does, or be a healthy volunteer.
  • If affected, you need a doctor outside the National Institutes of Health (NIH) for your routine care.
  • You must be willing to sign a consent form (or have a parent or legal guardian do so).
  • Healthy volunteers must have no personal or family history of DPPM and no symptoms.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04602325Recruiting
Blood and brain injury biomarker study for inherited metabolic disorders

This trial studies blood and other measurable signs (biomarkers) that may reflect brain injury after certain inherited metabolic conditions. Results may help doctors better detect and understand brain effects from these illnesses, especially episodes that affect the brain.

Washington D.C., District of Columbia
NCT00029965Recruiting
Understanding rare storage diseases over time

This study follows people with rare genetic conditions (GM1, GM2, sialidosis, or galactosialidosis) that affect how the body breaks down certain substances in cells. Researchers track how these diseases progress to better understand them and potentially help future patients.

Bethesda, Maryland
NCT01780168Recruiting
Study of metabolism, infection, and immunity in mitochondrial disease

This study looks at how metabolism, infections, and the immune system work together in people with mitochondrial disease. It aims to learn more about the condition and may help guide future treatments.

Bethesda, Maryland
NCT00237315Recruiting
Long-term study of urea cycle disorders in affected families

This study follows people with urea cycle disorders (and some people who are very likely to have one) over time. It aims to better understand how these rare enzyme problems affect health, using medical tests and family information.

Los Angeles, California
NCT03056794Recruiting
Study of genetic and natural history of PDC deficiency

This study looks at how pyruvate dehydrogenase complex (PDC) deficiency affects people over time and what genes are involved. It mainly helps by building genetic and health data, which may improve future care and understanding of the condition.

Pittsburgh, Pennsylvania
NCT05659901Recruiting
Study tracks symptoms and test results in PLP1-confirmed PMD

This study follows children with Pelizaeus-Merzbacher disease (PMD) who have a specific genetic change (PLP1 duplication). It aims to learn which body measurements (“biomarkers”) and symptoms change over time, to better understand disease progression.

Atlanta, Georgia

Hear when a new Metabolic Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.